Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile rekombinantný canarypox vírus (vcp2017 vírus) - immunologicals pre kone, kone, immunologicals - kone - aktívna imunizácia koní od piatich mesiacov veku proti západonílskej chorobe znížením počtu virémických koní. ak sú prítomné klinické príznaky, ich trvanie a závažnosť sú znížené.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 vírus - immunologicals, Živé vírusové vakcíny koní vírus chrípky - kone - aktívna imunizácia koní štyroch mesiacov alebo starších proti chrípke koní na zníženie klinických príznakov a vylučovanie vírusu po infekcii.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 vírus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - kone - aktívna imunizácia koní štyroch mesiacov alebo starších proti chrípke koní na zníženie klinických príznakov a vylučovania vírusu po infekcii a proti tetanu na prevenciu úmrtnosti.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insulins a analógy pre vstrekovanie, stredne-herectvo - cats; dogs - na liečbu diabetes mellitus u mačiek a psov dosiahnuť zníženie hyperglycaemia a zlepšenie spojené klinické príznaky.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - mačací leukémia vírus rekombinantný canarypox vírus (vcp97) - immunologicals pre felidae, - mačky - aktívna imunizácia mačiek vo veku 8 týždňov alebo starších proti mačacej leukémii na prevenciu pretrvávajúcej virémie a klinických príznakov súvisiacej choroby. nástup imunity bol preukázaný 2 týždne po primárnej vakcinácii. trvanie imunity je jeden rok po poslednej vakcinácii.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vírus vcp65 - imunologické - mačky - aktívna imunizácia mačiek vo veku 12 týždňov a starších s cieľom zabrániť úmrtnosti spôsobenej infekciou besnotou. nástup imunity: 4 týždne po základnom očkovaní. trvanie imunity po primárnom očkovaní: 1 rok. trvanie imunity po revakcinácii: 3 roky.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals pre felidae, - mačky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovaščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals pre felidae, - mačky - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. následky imunitného systému boli preukázané jeden týždeň po primárnom očkovaní proti rhinotracheitíde, kalicivíru, chlamydophila felis a panleukopénii. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.